HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on personalized cardiac care, announced it will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2025. The company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones, according to a press release issued on Oct. 30, 2025.
The upcoming call follows HeartBeam's recent FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024. The company's 12-lead ECG synthesis software is currently under FDA review, and investors will be keen to hear about any developments regarding this submission. HeartBeam is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a standard 12-lead ECG. This platform technology aims to enable portable devices that can be used wherever the patient is, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities.
HeartBeam holds over 20 issued patents related to its technology enablement. The company's forward-looking statements indicate that actual results may differ materially due to risks and uncertainties, including those detailed in its SEC filings. The full press release is available at https://ibn.fm/5mXsb, and the latest news and updates can be found in the company's newsroom at https://ibn.fm/BEAT.
The conference call will provide a critical opportunity for analysts and investors to assess the company's progress toward commercializing its 3D ECG technology. With FDA clearance for arrhythmia assessment already secured, the market is watching for the outcome of the 12-lead ECG synthesis software review. If approved, this could significantly expand the company's addressable market, enabling remote monitoring and early detection of heart attacks and other acute conditions.
HeartBeam's approach represents a paradigm shift in cardiac care, moving from clinic-based ECGs to personal, portable devices. The company's ability to synthesize 3D signals into a 12-lead ECG could make advanced cardiac monitoring accessible to patients at home, potentially reducing hospital visits and improving outcomes. As the company prepares for commercialization, the third quarter results and regulatory updates will be pivotal in determining its near-term trajectory.
